111 results about "Protein markers" patented technology

The invention discloses a gastric cancer biomarker composition as well as a screening method and application thereof, and belongs to the technical field of bioinformatics. The screening method of the gastric cancer biomarker composition comprises the following steps: firstly, collecting blood specimens of a gastric cancer patient and a healthy control, carrying out high-throughput plasma proteomics detection, and screening out differential expression proteins; and verifying the candidate protein markers by using a prospective queue in the British biological sample library, and finally determining 17 core proteins to obtain the gastric cancer biomarker composition. A gastric cancer risk prediction model is constructed by combining clinical risk factors and protein expression levels of gastric cancer biomarkers. The gastric cancer risk prediction model constructed by the invention can realize accurate layering of gastric cancer risks, decision curve analysis shows that the net benefit of the model is obviously superior to that of a traditional screening method, and an efficient tool is provided for early warning and personalized intervention of gastric cancer.

The invention relates to the field of medical informatics, and provides a diabetic nephropathy risk prediction method and system based on a protein marker. The method comprises the following steps: detecting the concentration of a protein marker in a plasma sample of a diabetic to obtain plasma protein marker concentration data; performing longitudinal correlation analysis on the protein markers according to the plasma protein marker concentration data to obtain the kidney disease related protein markers; performing feature screening on the kidney disease related protein marker combination to obtain a core protein marker; establishing a nephropathy risk prediction model through the clinical parameters of the diabetic patient and the core protein marker combination; and outputting a nephropathy risk prediction result of the patient to be detected through the nephropathy risk prediction model. The advanced intervention of the diabetic nephropathy is realized, and the prediction accuracy of the diabetic nephropathy is improved.

The invention provides a method and a system for predicting early gastric cancer prognosis by a circulating marker, and relates to the technical field of auxiliary diagnosis. The method comprises the following steps: performing multi-omics detection on a blood sample based on a preset sampling time sequence to obtain a multi-dimensional time sequence characteristic data set containing three groups of heterogeneous data of circulating tumor DNA, exosomes and protein markers; calculating a change slope and a fluctuation variance of the heterogeneous data in adjacent time sequence intervals, constructing a dynamic variation feature matrix in combination with a standard attenuation weighting factor, and deeply mining spatial cross-correlation and sequence dependence features of the matrix to generate a multi-modal fusion feature fingerprint; and performing regression operation on the feature fingerprints by using an integrated learning stack model to obtain a dynamic prognosis risk score, and further retrieving a risk hierarchical mapping table to generate a prognosis evaluation result containing a survival curve. According to the method, multi-modal heterogeneous data can be effectively fused, the biological dynamic characteristics in the tumor postoperative recovery phase are captured, and the accuracy and timeliness of early gastric cancer prognosis prediction are remarkably improved.

The invention relates to an immune Raman multicolor imaging kit for liver cancer prediction and evaluation, the immune Raman multicolor imaging kit comprises five Raman probes, and the Raman probes are composed of Raman balls and antibodies connected to the surfaces of the Raman balls; wherein the Raman sphere is formed by polymerizing a triple bond monomer and (i) acrylic acid or (ii) styrene and acrylic acid, the particle size is 10-100 nm, and the Raman shift is 1800-2800 cm <-1 >; antibodies of the five Raman probes are respectively selected from one of an AFP antibody, an HBX antibody, a GPC3 antibody, a GS antibody and a CD34 antibody. The immune Raman multicolor imaging reagent and kit provided by the invention can realize one-step marking and multiple color development of five liver cancer related protein markers in the same liver tissue slice. Compared with a multiple fluorescence immunohistochemical technology, the method has remarkable advantages in efficiency and precision. Experiments show that the detection result is consistent with the clinical diagnosis result, and the application potential is huge.

The invention discloses an application of a biomarker in typing of polymorphic glioblastoma, and the biomarker is combined by selecting at least one of the following categories: at least one of a plurality of gene markers for identifying a proliferative type, a protein marker DLL3 and / or Ki67, a protein marker DL3 and / or Ki67, a protein marker DL3 and / or Ki67, a protein marker DL3 and / or Ki67, a protein marker DL3 and / or Ki67, and a protein marker DL3 and / or Ki67. At least one of a plurality of gene markers for identifying the neurosynaptic type, a protein marker GRMM3 and / or FGFR2; at least one of a plurality of gene markers for identifying the metabolic type, a protein marker P16; and at least one of a plurality of gene markers for identifying the immune regulation type, and at least one of protein markers CD44, C1R and Ki67. The application provides comprehensive features of EAS-GBM, and enhances understanding of occurrence, clinical stratification and treatment strategies of different ancestral tumors.

The invention relates to a urine protein marker for depression and bipolar affective disorder and application of the urine protein marker in early diagnosis. Specifically, the invention relates to application of a reagent for detecting the content of protein in urine of a subject in preparation of a reagent for diagnosing depression and bipolar affective disorder, and the protein in the urine is selected from the following combinations: Uniprot ID: P11766, H7BY57, O95967, O95433, K7ELM9, P15328 and P68371.

The invention relates to the technical field of western blot analysis, and discloses a full-automatic micro western blot analyzer and an analysis method thereof. The full-automatic micro protein immunoblotting analyzer comprises a full-automatic control system, a horizontal control system, a protein separation system, a temperature control system, a liquid path control system, an ultraviolet curing module, an antibody incubation module and a chip scanning module, the horizontal control system controls the protein separation system to horizontally move and correct; the protein separation system carries out protein separation; the temperature control system is used for carrying out constant-temperature control and temperature adjustment; the liquid path control system is used for filling a constant-temperature reagent into the protein separation system and extracting waste liquid; the ultraviolet light curing module is used for carrying out in-situ immobilization on the separated protein; the antibody incubation module is used for performing antibody incubation on the fixed protein marker; and the chip scanning module is used for chip result reading and data processing. According to the invention, full-automatic control, accurate temperature control and automatic horizontal correction can be realized.

The application discloses an electrochemical sensor for detecting IBD protein markers and a preparation method thereof. The electrochemical sensor is composed of a CNT-embedded semi-cured PDMS flexible substrate, deposited gold nanoparticles and a nucleic acid sensing layer. The nucleic acid sensing layer comprises a tumor necrosis factor-alpha sensor, an interleukin 6 sensor, an interleukin 8 sensor, a transforming growth factor beta 1 sensor, a reference electrode and a counter electrode. The tumor necrosis factor-alpha sensor, the interleukin 6 sensor, the interleukin 8 sensor and the transforming growth factor beta 1 sensor all adopt single-stranded aptamers modified by a signal molecule methylene blue, and the nucleotide sequences corresponding to the single-stranded aptamers are SEQ ID NO. 1-4. The application can improve the modulus matching of the sensor and human tissue and excellent biocompatibility, realize accurate detection of low-concentration biomarkers and stable signal output of the sensor under a strain working condition.

The application belongs to the technical field of biomedicine, and particularly relates to a construction system of a cerebral amyloid angiopathy recognition model, a storage medium and a kit. Based on plasma proteomic data of cerebral amyloid angiopathy patients and normal old controls, six key protein markers closely related to cerebral amyloid angiopathy are screened out. The application also provides a model for recognizing cerebral amyloid angiopathy based on a combination of six plasma protein biomarkers. The model shows excellent performance in multiple independent data sets, can accurately distinguish cerebral amyloid angiopathy patients from normal old controls, and further distinguish cerebral amyloid angiopathy patients with high-risk cerebral hemorrhage risk from those with low-risk cerebral hemorrhage risk. The application provides a new tool for early diagnosis and hemorrhage risk assessment of cerebral amyloid angiopathy.

The present invention provides methods and compositions based on a non-naturally occurring nucleic acid construct encoding a fusion protein for quantifying secretion levels in an individual cell, which may comprise a protein sequence comprising a cytoplasmic domain, a transmembrane domain, and a vesicular domain, wherein the vesicular domain may comprise a sequence of protein marks, wherein upon expression of the fusion protein by a cell, the fusion protein localizes to the membrane of a secretory vesicle such that the protein mark is located in the lumen of the secretory vesicle, and wherein the protein mark binds to a cell-impermeable marker;whereby, after the secretion of the contents of the secretory vesicle, the protein tag is exposed to the cell-impermeable marker, the fusion protein is recycled back into the cell, and the individual cell is tagged with the marker in relation to the amount of secretion.

The present invention belongs to the field of bioproteomics technology, specifically relating to a hair identification method based on 4D Label-Free technology and the protein markers used to identify hair. This identification method utilizes 4D Label-Free analysis technology to obtain differentially expressed protein markers capable of distinguishing between human axillary and pubic hair samples. The protein GPRC5D described in the present invention is a protein marker specific for axillary hair, and CTNNBIP1 is a protein marker specific for pubic hair. The hair protein markers obtained in this invention can be used to identify case-related hair samples as pubic hair, which is of great significance for the determination of criminal cases.

The invention discloses a plasma protein marker for identifying or assisting in identifying parathyroid cancer and parathyroid adenoma and application of the plasma protein marker. The method comprises the following steps: firstly, collecting plasma specimens of a parathyroid carcinoma patient and a parathyroid adenoma patient before an operation, and screening through an unmarked quantitative proteomics technology to obtain 24 differential expression proteins; on the basis of the other part of plasma specimens of the parathyroid carcinoma patient and the parathyroid adenoma patient collected before the operation, the 24 differential expression proteins are verified through a parallel reaction monitoring technology; finally, three plasma protein markers (myoglobin, coronin-1A and a polyimmunoglobulin receptor) which can be used for identifying the parathyroid carcinoma and the parathyroid adenoma are obtained. Experiments prove that the plasma protein marker or the combination thereof can be used for auxiliary differential diagnosis of parathyroid carcinoma and parathyroid adenoma, and has important significance for improving the accuracy of preoperative diagnosis of parathyroid carcinoma.

The invention provides a multi-omics integrated marker for early screening of colorectal cancer, which comprises an lncRNA marker combination, a protein marker combination, an mRNA marker combination, a metabolism marker combination and a methylation marker combination, and relates to the technical field of gene detection and medical treatment. According to the invention, 11 groups of colorectal cancer tissues and para-carcinoma tissues paired with the colorectal cancer tissues are subjected to transcriptome, proteome and metabolome sequencing, and 61 cases of colorectal cancer tissues and 24 cases of para-carcinoma tissues are subjected to simplified methylation sequencing; by integrating and analyzing the multi-omics data, a multi-level interaction network is obtained, and the network contains lncRNA, protein, mRNA, metabolites and DNA methylation markers which have a close interaction relationship, and has a wide application prospect in diagnosis and treatment of colorectal cancer.

Provided are diagnostic and treatment methods,based on plasma protein markers for neurodegenerative diseases such as mild cognitive impairment (MCI) and Alzheimer's Disease (AD),as well as kits for diagnosing and / or treating these condition.Machine learning systems and methods for assessing the risk for a subject having a neurodegenerative disease based on measured protein marker levels are also provided.

The invention discloses an ultra-stable red fluorescent protein. The fluorescent protein disclosed by the invention is a protein with an amino acid sequence SEQ ID No.4. Experiments prove that the fluorescent protein has excellent electron microscope sample preparation resistance, can retain more fluorescent signals after osmic acid treatment, and can tolerate embedding of Epon resin; meanwhile, the fluorescent protein has excellent thermal stability, and can retain more fluorescent signals at 90 DEG C; in addition, the fluorescent protein has high chemical stability and light stability. Based on the related properties of the fluorescent protein, the fluorescent protein can be used in the fields of protein labeling, various types of fluorescence imaging and super-resolution photoelectric correlated imaging, and is used for tracking the structural and morphological changes of samples such as proteins, subcellular organelles, local cell regions and cells; the kit can be used for packaging related viruses or transgenic animals, marking specific proteins, specific organelles or specific cells, and realizing rapid transparent tissue imaging and expansion super-resolution imaging.

The invention relates to screening and application of a chronic kidney disease plasma protein marker, and belongs to the technical field of plasma protein markers. The protein marker combination comprises 25 proteins such as de-integrin metalloproteinase 22, keratinoin, chitosanase 3-like protein 1, an XVIII type collagen alpha 1 chain, a VI type collagen alpha 3 chain, a growth differentiation factor 15, phospholipid globulin glycan 1, a renal injury factor 1, histidine-rich calcium binding protein, kallikrein related peptidase 4 and the like which are positively correlated with the chronic kidney disease. The kit also comprises seven proteins such as a contact protein 5, an Erb-b2 receptor tyrosine kinase 3, an Erb-b2 receptor tyrosine kinase 4, an insulin-like growth factor binding protein 3 and the like which are negatively related to the chronic kidney disease. Compared with previous cross section research or case contrast research, the protein related to chronic kidney disease incidence can be screened, and the causal time sequence of the protein and chronic kidney disease is clearer.

The application belongs to the technical field of molecular diagnosis, and particularly relates to a group of extracellular vesicle proteins as biomarkers for diagnosing abdominal aortic aneurysm and application. The application early diagnoses abdominal aortic aneurysm through determination of circulating extracellular vesicle protein markers, and provides an effective tool for diagnosis of abdominal aortic aneurysm. The extracellular vesicle protein marker is any one or two or more molecular marker combinations of interleukin-4 (IL-4), interleukin-6 (IL-6), monocyte chemotactic protein-1 (MCP-1), nerve growth factor (Neurturin) and tumor suppressor M (Oncostatin-M). The application uses proteins in extracellular vesicles as specific markers for early diagnosis of abdominal aortic aneurysm, which is a less applied field in current early diagnosis of AAA. The specific proteins in EVs may be directly related to the pathological process of AAA, and are different from conventional serum markers, and have higher specificity and sensitivity.

The invention discloses a biomarker combination for predicting the treatment effect of AK112 and application of the biomarker combination. The biomarker combination is prepared from APOE + KRT18-CCL20-macrophages, CD161 + CD8 + T cells, PDCD1, FGF2, diglyceride and lysophosphatidylcholine. Flow cytometry immunophenotypes (macrophage subgroups and T cell subgroups), plasma protein markers (PDCD1 and FGF2) and metabolic micromolecules (diglyceride and lysophosphatidylcholine) are combined to form a cross-omics prediction system, the combination can synchronously evaluate dual action mechanisms (immune activation and blood vessel regulation) of AK112, the technical bottleneck of single dimension of existing liquid biopsy is broken through, and the application prospect is wide. And a non-invasive dynamic monitoring tool is provided for accurately screening AK112 benefit people.

Disclosed herein is a soluble protein signature from the tumor microenvironment that can predict overall survival post-surgery in pancreatic adenocarcinoma. The disclosed protein signatures provide a precision approach to surgical therapy for patients with pancreatic cancer. Also disclosed herein is a soluble protein signature from the tumor microenvironment that can diagnose pancreatic ductal adenocarcinoma (PDAC). Also disclosed herein are proteins that can be used to accurately normalize protein levels in a pancreatic sample.

The application discloses a combination of protein markers and clinical indexes related to leukoaraiosis, products and applications thereof. The protein marker combination comprises P05198, P00966, Q8IZP0 and P48061. The clinical indexes comprise MMSE, CTTtrail1 and SDMT. The application also provides applications, kits and computer program products of the combination. The combination can be used for quickly, conveniently and economically identifying leukoaraiosis. The computer program product has good model performance and shows relatively accurate prediction ability, and has clinical use and promotion value.

The invention discloses a space-time marking method for a living cell endoplasmic reticulum proteome, and belongs to the field of proteomics. The technical problem to be solved by the invention is how to mark endoplasmic reticulum proteins. The space-time labeling method for the living cell endoplasmic reticulum proteome comprises the following steps: treating a cell to be detected by using a metal iridium complex Ir3 and a thiomethylene quinone precursor probe to obtain the cell treated by the Ir3 and the probe; the thiomethylene quinone precursor probe is a compound or a derivative thereof obtained by connecting biotin and a thiomethylene quinone precursor with a linking group; and irradiating the Ir3 and the cells treated by the probe with blue light to realize space-time labeling of the endoplasmic reticulum proteome of the living cells. The method disclosed by the invention can be used for performing space-time labeling on the endoplasmic reticulum proteome of the living cell, has the characteristics of high specificity and in-situ protein labeling, and has nanoscale space-time resolution.

Provided are diagnostic and treatment methods,based on plasma protein markers for neurodegenerative diseases such as mild cognitive impairment (MCI) and Alzheimer's Disease (AD),as well as kits for diagnosing and / or treating these condition.Machine learning systems and methods for assessing the risk for a subject having a neurodegenerative disease based on measured protein marker levels are also provided.

The invention belongs to the field of biological detection of protein markers, and relates to identification of high-temperature-resistant rice, in particular to a protein marker of high-temperature-resistant rice and application of the protein marker. The protein marker of the high-temperature-resistant rice is a rice protein OsCOX5b-2, and the amino acid sequence of the protein marker is as shown in SEQ ID No. 1. The high-temperature-resistant rice is high-temperature-resistant japonica rice. The protein marker is applied to identification of high-temperature-resistant rice. Compared with other reported stress-resistant protein markers, the high-temperature stress protein marker in the flowering period screened for japonica rice varieties in the northern Henan rice area is more suitable for japonica rice breeding materials in the area, and the japonica rice breeding materials in the area can be more efficiently and accurately screened.

The present disclosure relates to manufacturing transferrin binding proteins. Specifically, the present disclosure relates to a simple, scalable, commercially viable fermentation and purification process for obtaining recombinant transferrin binding protein (rTbp-B) along with high recovery, low impurity / aggregate content, and at the same time retains the integrity of the protein. The method uses a single chromatographic step and does not require tagging of proteins as compared to multiple chromatographic steps used previously and still manages to provide r-Tbp-B with at least 95 % purity.

This invention discloses the application of urinary microvesicle proteins as diagnostic markers for renal cell carcinoma. The protein markers derived from urinary extracellular vesicles associated with clear cell renal carcinoma are characterized by being selected from one or more of the following proteins: CSPG4, AQP1, PLIN2, CA9, and HAVCR1. The invention also describes the application of reagents for detecting these protein markers in the preparation of auxiliary diagnostic reagents for clear cell renal carcinoma. The inventors, using flow cytometry, analyzed 200 patients and found that five proteins derived from urinary extracellular vesicles could effectively distinguish patients with clear cell renal carcinoma from controls (including healthy individuals, patients with benign renal tumors, patients with benign renal cysts, and patients with chronic kidney disease).

Protein markers MIB1 and / or YBX1 for distinguishing benign and malignant pulmonary nodules, the use of a detection reagent for detecting the protein level of protein markers MIB1 and / or YBX1 in a biological sample in the preparation of a product for diagnosing benign and malignant pulmonary nodules, and a product for diagnosing benign and malignant pulmonary nodules, which product comprises the detection reagent for detecting the protein level of protein markers MIB1 and / or YBX1 in a biological sample. The detection of the expression level of MIB 1 or YbX1 alone or the co-expression level of the two in a biological sample can distinguish benign and malignant pulmonary nodules.

The present invention relates to an integrated centrifugal device and method for analyte processing, particularly for the separation, enrichment, labeling, and analysis of nanovesicles such as extracellular vesicles (EVs). The device leverages a compact, rotatable substrate to execute multi-step assay protocols that may include chromatographic separation, centripetal fluid transport, immuno-capture, and protein labeling, all under low-speed centrifugal conditions. The device architecture enables automated, hands-free operation without requiring ultracentrifugation or specialized personnel. Fluidic modules including sedimentation, chromatography, displacement, and multiple assay chambers may be functionally integrated through a series of valves, channels, and immiscible liquid-based displacement mechanisms, facilitating precise sample handling, minimal loss, and multiplexed analysis.

The application discloses a gastric cancer biomarker composition and a screening method and application thereof, and belongs to the technical field of bioinformatics; the screening method of the gastric cancer biomarker composition comprises the following steps: collecting blood samples of gastric cancer patients and healthy controls, performing high-throughput plasma proteomics detection, and screening out differentially expressed proteins; the candidate protein markers are verified by using a prospective cohort in the UK BioSample Bank, 17 kinds of core proteins are finally determined, and the gastric cancer biomarker composition is obtained; and a gastric cancer risk prediction model is constructed by combining clinical risk factors and the protein expression levels of the gastric cancer biomarkers. The gastric cancer risk prediction model constructed by the application can realize precise stratification of gastric cancer risks, and decision curve analysis shows that the net benefit of the gastric cancer risk prediction model is significantly better than that of a traditional screening method, so that the gastric cancer risk prediction model provides an efficient tool for early warning and personalized intervention of gastric cancer.

The application provides a protein marker for predicting the sensitivity of adjuvant chemotherapy of an ovarian cancer patient and an application, based on proteomics data of an ovarian cancer tissue sample, combining a preliminary screening model and a classification model and PRM technology, screening a plurality of protein markers with representative meanings for predicting the sensitivity of adjuvant chemotherapy of an ovarian cancer patient after neoadjuvant therapy, training an ovarian cancer patient chemotherapy sensitivity prediction model by using the screened protein markers, predicting the chemotherapy sensitivity of an ovarian cancer patient who has not undergone adjuvant therapy by using the ovarian cancer patient chemotherapy sensitivity prediction model, if the chemotherapy sensitivity is low, it means that the probability of recurrence of the patient after 6 months of adjuvant therapy is high, so medical staff can adjust the treatment plan accordingly, avoid unnecessary chemotherapy treatment for ovarian cancer patients, and play a preventive effect.